These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33534766)

  • 21. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002.
    Cetron MS; Marfin AA; Julian KG; Gubler DJ; Sharp DJ; Barwick RS; Weld LH; Chen R; Clover RD; Deseda-Tous J; Marchessault V; Offit PA; Monath TP
    MMWR Recomm Rep; 2002 Nov; 51(RR-17):1-11; quiz CE1-4. PubMed ID: 12437192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines.
    Jong EC; Kaplan KM; Eves KA; Taddeo CA; Lakkis HD; Kuter BJ
    J Travel Med; 2002; 9(2):66-70. PubMed ID: 12044272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence, drivers and global health implications of the 2019/2020 yellow fever sporadic outbreaks in Sub-Saharan Africa.
    Uchenna Emeribe A; Nasir Abdullahi I; O R Ajagbe O; Egede Ugwu C; Oloche Onoja S; Dahiru Abubakar S; Modesta Umeozuru C; Sunday Animasaun O; Omoruyi Omosigho P; Mukhtar Danmusa U; Alhaji Baba Mallam M; Saidu Aminu M; Yahaya H; Oyewusi S
    Pathog Dis; 2021 Apr; 79(4):. PubMed ID: 33739369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of travel medicine practice by yellow fever vaccination centers in England, Wales, and Northern Ireland.
    Boddington NL; Simons H; Launders N; Gawthrop M; Stillwell A; Wong C; Mathewson J; Hill DR
    J Travel Med; 2012; 19(2):84-91. PubMed ID: 22414032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?
    Baba MM; Ikusemoran M
    Biochem Biophys Res Commun; 2017 Oct; 492(4):548-557. PubMed ID: 28109882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet.
    Lammert SM; Rao SR; Jentes ES; Fairley JK; Erskine S; Walker AT; Hagmann SH; Sotir MJ; Ryan ET; LaRocque RC
    J Travel Med; 2016 Jul; 24(1):. PubMed ID: 27799502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of yellow fever vaccination practice in England.
    Bryant N; Tucker R; Simons H; Bailey S; Mathewson J; Lea G; Hill DR
    J Travel Med; 2008; 15(5):287-93. PubMed ID: 19006500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linking yellow fever vaccinator approval and renewal with training in travel medicine in New Zealand.
    O'Brien B; Leggat PA
    Travel Med Infect Dis; 2010 Jul; 8(4):210-2. PubMed ID: 20970723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fractional dosing of yellow fever vaccine during shortages: perspective from Canada.
    Teitelbaum P; Bui YG; Libman M; McCarthy A
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346564
    [No Abstract]   [Full Text] [Related]  

  • 31. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
    Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
    Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
    Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
    Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.
    Jentes ES; Poumerol G; Gershman MD; Hill DR; Lemarchand J; Lewis RF; Staples JE; Tomori O; Wilder-Smith A; Monath TP;
    Lancet Infect Dis; 2011 Aug; 11(8):622-32. PubMed ID: 21798462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events following yellow fever vaccination in immunocompromised persons.
    Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina.
    Ripoll C; Ponce A; Wilson MM; Sharif N; Vides JB; Armoni J; Teuwen DE
    Hum Vaccin; 2008; 4(2):121-6. PubMed ID: 18382132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of anaphylaxis to YF-VAX® yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018.
    McClenathan BM; Taylor JN; Housel LA; Ryan M
    J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38051650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of the 17D-204 yellow fever vaccine.
    Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F
    Vaccine; 2015 Oct; 33(41):5432-5436. PubMed ID: 26314624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.